Suchergebnisse - "Casajust, Paula"

PubPharm (34)

1

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease : EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia

enthalten in: Cardiovascular diabetology | 2023

von Vistisen, D. | Carstensen, B. | Elisabetta, P. | +54

2

Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe

enthalten in: The Journal of asthma : official journal of the Association for the Care of Asthma | 2023

von Morales, D. | Ostropolets, A. | Lai, L. | +37

3

Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors : Real world evidence from the Nordic EMPRISE study

enthalten in: Diabetes, obesity & metabolism | 2023

von Nyström, T. | Toresson Grip, E. | Gunnarsson, J. | +5

4

Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors : Real world evidence from the Nordic EMPRISE study

enthalten in: Diabetes, Obesity and Metabolism | 2023

von Nyström, T. | Toresson Grip, E. | Gunnarsson, J. | +4

5

Characteristics and outcomes of 627 044 COVID-19 patients with and without obesity in the United States, Spain, and the United Kingdom

enthalten in: bioRxiv.org | 2022

von Recalde, M. | Roel, E. | Pistillo, A. | +35

6

Bias, precision and timeliness of historical (background) rate comparison methods for vaccine safety monitoring: an empirical multi-database analysis

enthalten in: bioRxiv.org | 2022

von Li, X. | Lai, L. | Ostropolets, A. | +13

7

Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS

enthalten in: ResearchSquare.com | 2022

von Prieto-Alhambra, D. | Kostka, K. | Duarte-Salles, T. | +72

8

Current Approaches to Vaccine Safety Using Observational Data : A Rationale for the EUMAEUS (Evaluating Use of Methods for Adverse Events Under Surveillance-for Vaccines) Study Design

enthalten in: Frontiers in pharmacology | 2022

von Lai, L. | Arshad, F. | Areia, C. | +12

9

Unraveling COVID-19 : A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS

enthalten in: Clinical epidemiology | 2022

von Kostka, K. | Duarte-Salles, T. | Prats-Uribe, A. | +72

UpdateOf: Res Sq. 2021 Mar 01;:. - PMID 33688639

10

Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom

enthalten in: International journal of obesity (2005) | 2021

von Recalde, M. | Roel, E. | Pistillo, A. | +36